Search research articles
Contact Us
Filters
Showing results (71-80 of 79) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 79 results.
The Lancet. Oncology
|
July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Yoon-Koo Kang, Suzanne George, Robin L Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Hans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Nature Medicine
|
January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Michael C Heinrich, Robin L Jones, Suzanne George, et al.
Nature Medicine
|
May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
Priscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2025
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Amin H Nassar, Sarah Abou Alaiwi, Talal El Zarif, et al.
The Bone & Joint Journal
|
June 9, 2026
A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM)
Lee M Jeys, Eduardo Botello, Richard Boyle, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 79) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 79 results.
The Lancet. Oncology
|
July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Yoon-Koo Kang, Suzanne George, Robin L Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Hans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Nature Medicine
|
January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Michael C Heinrich, Robin L Jones, Suzanne George, et al.
Nature Medicine
|
May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
Priscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2025
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Amin H Nassar, Sarah Abou Alaiwi, Talal El Zarif, et al.
The Bone & Joint Journal
|
June 9, 2026
A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM)
Lee M Jeys, Eduardo Botello, Richard Boyle, et al.
Page
of 8